This startup develops a mental well-being platform that uses EEG technology to understand and accelerate recovery from depression. Their home-use medical devices provide data-driven insights to help individuals manage their mental health.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for assessing and treating depression often lack objective biomarkers, making it difficult to personalize and optimize treatment strategies. The absence of clinically translated biomarkers hinders the development of targeted therapies and devices for mental health conditions.
Solution
Resonait is developing home-use medical devices that leverage EEG technology to provide data-driven insights for managing and accelerating recovery from depression. By analyzing real-time EEG data, the platform aims to identify and translate clinically relevant biomarkers related to depression, particularly focusing on the default mode network (DMN). The devices facilitate a new paradigm of depression treatment and measurement, enabling personalized interventions based on neural network modulation approaches. Resonait's technology supports the prediction of Transcranial Magnetic Stimulation (TMS) outcomes and the validation of neural network modulation techniques.
Target Audience
The primary target audience includes individuals seeking personalized and data-driven approaches to managing their depression, as well as clinicians and researchers in the field of mental health.
Features
- Home-use EEG medical devices for continuous monitoring of brain activity
- Real-time EEG analysis to identify biomarkers associated with depression
- Focus on the default mode network (DMN) as a key indicator of mental health status
- Neural network modulation approach for personalized treatment strategies
- Prediction of Transcranial Magnetic Stimulation (TMS) outcomes using EEG data
- Collaboration with research institutions to validate neural network modulation techniques